張明明,于悅卿,趙培,楊朝菊,高偉,李亞麗,李芳
(河北省人民醫(yī)院 1.檢驗(yàn)科,2.生殖遺傳科,3.風(fēng)濕免疫科,河北 石家莊 050051)
·論 著·
心肌梗死患者Lp-PLA2基因Y160X位點(diǎn)多態(tài)性檢測(cè)的意義
張明明1,于悅卿1,趙培1,楊朝菊1,高偉1,李亞麗2,李芳3
(河北省人民醫(yī)院 1.檢驗(yàn)科,2.生殖遺傳科,3.風(fēng)濕免疫科,河北 石家莊 050051)
目的:檢測(cè)Lp-PLA2基因Y160X位點(diǎn)突變與心肌梗死(MI)的關(guān)系。方法:檢測(cè)病例組和對(duì)照組Lp-PLA2基因多態(tài)性,Logistic回歸分析Lp-PLA2多態(tài)性與MI的關(guān)系,以及病例組和對(duì)照組血脂、血糖、Lp-PLA2、超敏C反應(yīng)蛋白(HsCRP)、白介素-6(IL-6)、白介素-10(IL-10)水平,分析這些指標(biāo)與MI及Lp-PLA2基因突變的關(guān)系。結(jié)果:病例組總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDLC)、Lp-PLA2、HsCRP、IL-6水平及家族史陽性率高于對(duì)照組,HDLC、IL-10水平低于對(duì)照組(P<0.05);發(fā)病1周、1個(gè)月時(shí)Lp-PLA2、HsCRP、IL-6水平下降,IL-10水平上升(P<0.05)。Lp-PLA2基因型是MI的獨(dú)立危險(xiǎn)因素。結(jié)論:Lp-PLA2基因Y160X位點(diǎn)突變可能是MI的原因。
脂蛋白相關(guān)磷脂酶A2基因;基因多態(tài)性;心肌梗死;遺傳易感性
研究發(fā)現(xiàn),脂蛋白相關(guān)磷脂酶A2(lipoprotein associated phospholipase A2,Lp-PLA2)基因突變與冠心病有關(guān)[1-2],但未見Lp-PLA2基因Y160X突變與心肌梗死(MI)關(guān)系的報(bào)道。本研究對(duì)487例MI患者和450例健康體檢者Lp-PLA2基因Y160X位點(diǎn)多態(tài)性和血清Lp-PLA2、炎癥因子的差異進(jìn)行比較分析,探討Lp-PLA2基因突變與MI的關(guān)系。
1.1 研究對(duì)象
選擇2014年4月至2016年4月在我院確診住院的MI患者487例為病例組,其中男294例,女193例,中位年齡47歲。選擇同期來我院體檢的健康人450例為對(duì)照組,男272例,女178例,中位年齡47歲。
1.2 血清采集
病例組于入院24h內(nèi)取空腹靜脈血7ml,2ml用于提取DNA,5ml分離血清,檢測(cè)血脂、血糖(Glu)、Lp-PLA2、超敏C反應(yīng)蛋白(Hs-CRP)、白介素-6(IL-6)及IL-10。入院后1 周和1個(gè)月復(fù)查上述指標(biāo)。對(duì)照組抽取空腹靜脈血7ml,檢測(cè)上述指標(biāo)。
1.3 實(shí)驗(yàn)室檢測(cè)
Beckman AU5821生化儀測(cè)定血清總膽固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDLC)、低密度脂蛋白(LDLC)、Glu水平。Abbott ARCHITECT plus i2000 SR電發(fā)光分析儀檢測(cè)血清Lp-PLA2。Siemens BNⅡ system蛋白分析儀檢測(cè)血清中Hs-CRP水平。ELISA法檢測(cè)IL-6 、IL-10水平,酶標(biāo)儀450nm處讀取OD值。按文獻(xiàn)[3]檢測(cè)Lp-PLA2基因Y160X位點(diǎn)多態(tài)性。
1.4 統(tǒng)計(jì)學(xué)處理
數(shù)據(jù)采用SPSS16.0軟件進(jìn)行統(tǒng)計(jì)處理。采用t檢驗(yàn),F(xiàn)檢驗(yàn)、χ2檢驗(yàn)、Spearman相關(guān)分析、多因素Logistic回歸分析進(jìn)行處理。以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 兩組基本資料比較
病例組TC、TG、LDLC、Lp-PLA2、HsCRP、IL-6水平及家族史陽性率顯著高于對(duì)照組,HDLC、IL-10水平明顯低于對(duì)照組(P<0.01);Glu水平兩組差異無統(tǒng)計(jì)學(xué)意義(P>0.05),見表1。



組 別n年齡/歲家族史TC/mmol·L-1TG/mmol·L-1HDLC/mmol·L-1LDLC/mmol·L-1病例組48747.9±10.3183(37.6)5.19±1.021.85±0.610.77±0.153.58±0.77對(duì)照組45048.0±11.455(12.2)4.19±0.591.07±0.291.27±0.282.43±0.42t/χ2值-0.14179.00218.17624.670-34.42328.058P值0.888<0.001<0.001<0.001<0.001<0.001組 別nGlu/mmol·L-1LP-PLA2/ng·ml-1HsCRP/mg·L-1IL-6/pg·ml-1IL-10/pg·ml-1病例組4874.88±0.55384.2±75.823.2±4.6573.2±98.7192.5±35.7對(duì)照組4504.83±0.46114.9±29.85.12±0.84148.8±26.8409.6±77.5t值1.50370.49782.11888.255-55.75P值0.103<0.001<0.001<0.001<0.001
注:括號(hào)內(nèi)為百分比
2.2 兩組不同時(shí)間Lp-PLA2、炎癥因子水平比較
Lp-PLA2、HsCRP、IL-6水平隨疾病時(shí)間逐漸下降,IL-10水平逐漸上升。發(fā)病1個(gè)月后HsCRP、IL-6的水平下降至對(duì)照組水平,IL-10水平上升至對(duì)照組水平(P>0.05),但Lp-PLA2的水平仍高于對(duì)照組(P<0.05),見表2。



組 別nLp-PLA2/ng·ml-1HsCRP/mg·L-1IL-6/pg·ml-1IL-10/pg·ml-1病例組487 入院時(shí)384.2±75.8ac23.2±4.6ac573.2±98.7ac192.5±35.7ac 入院1周282.4±57.6ab14.6±3.3ab328.5±56.3ab289.4±33.9ab 入院1個(gè)月168.4±44.8abc5.20±0.58bc150.3±27.2bc396.2±58.8bc對(duì)照組450114.9±29.85.12±0.84148.8±26.8409.6±77.5
與對(duì)照組比較,aP<0.05;與同組入院時(shí)比較,bP<0.05;與同組入院1周時(shí)比較,cP<0.05
2.3 Lp-PLA2基因第6外顯子Y160X位點(diǎn)多態(tài)性直接測(cè)序結(jié)果
該位點(diǎn)存在等位基因T和A,有3種基因型:AA(突變純合子)、AT(突變雜合子)、TT(野生型),見圖1。

圖1 Lp-PLA2基因Y160X位點(diǎn)多態(tài)性情況
Fig 1 Y160X site polymorphism of Lp-PLA2 gene
2.4 兩組Lp-PLA2基因Y160X位點(diǎn)基因型和等位基因頻率分布
病例組AA、AT基因型頻率明顯高于對(duì)照組(χ2=13.506,P=0.0002;χ2=49.997,P<0.001);病例組A等位基因頻率(20.0 %)明顯高于對(duì)照組(6.6%)(χ2=72.383,P<0.001),見表3。
2.5 病例組入院時(shí)血清Lp-PLA2、HsCRP、IL-6、IL-10之間的相關(guān)性
Spearman結(jié)果顯示,Lp-PLA2與HsCRP、IL-6呈正相關(guān)(r=0.4376;r=0.3152,均P<0.001),與IL-10負(fù)相關(guān)(r=-0.2755,P<0.001);HsCRP、IL-6與IL-10負(fù)相關(guān)(r=-0.4016;r=-0.2341,均P<0.001)。
2.6 Logistic回歸分析結(jié)果
以MI(無=0,有=1)為因變量,TC、TG、LDLC、HDLC、Lp-PLA2、HsCRP、IL-6、IL-10、Lp-PLA2基因Y160X位點(diǎn)基因型(TT=0,AT=1;AA=2)為自變量進(jìn)行Logistic回歸分析,結(jié)果顯示基因型與Lp-PLA2、MI有關(guān)(分別OR=9.863,95%CI4.107-21.331,P<0.001;OR=1.239,95%CI1.023-2.017,P=0.031),見表4。
表3 兩組Lp-PLA2基因Y160X位點(diǎn)多態(tài)性基因型和等位基因頻率分布 例
Tab 3 The frequency of genotype and alleles of Y160X site polymorphism of Lp-PLA2 gene in case group and control group case

組 別n基因型 TT AT AA 等位基因 T A 病例組487318(65.3)143(29.4)a26(5.3)a779(80.0)195(20.0)a對(duì)照組450396(88.0)49(10.9)5(1.1)841(93.4)59(6.6)
注:括號(hào)內(nèi)為百分比
與對(duì)照組比較,aP<0.05
表4 MI危險(xiǎn)因素多因素Logistic回歸分析結(jié)果
Tab 4 Results of Logistic regression analysis for risk factors of MI

變 量B值SE值Wald值df值P值OR值95%CI基因型2.3150.37236.5701<0.0019.8634.107-21.331Lp-PLA20.1450.2314.32710.0311.2391.023-2.017TC0.1340.1950.09410.6340.9140.798-1.139TG0.0450.0810.06910.7100.8390.713-1.094HDLC-0.1210.1971.06810.4371.4370.897-1.683LDLC0.2570.2943.29610.0821.2840.821-1.934HsCRP0.4210.2342.62410.2511.2390.738-1.776IL-60.5940.3931.92710.3421.3010.637-1.835IL-10-0.3600.4123.01410.1310.6970.436-1.096
在MI發(fā)病中遺傳因素、炎癥因子均發(fā)揮了作用[4-5]。Lp-PLA2與冠心病及炎癥因子有關(guān)。HsCRP是反映炎癥情況的靈敏指標(biāo)[6];IL-6具有刺激炎癥細(xì)胞的作用[7];IL-10能下調(diào)炎癥反應(yīng)[8]。本研究病例組Lp-PLA2、HsCRP、IL-6水平高于對(duì)照組,IL-10低于對(duì)照組,提示MI的過程有炎癥反應(yīng)參與,Lp-PLA2與MI有關(guān)。本研究還發(fā)現(xiàn),病例組的TC、TG、LDLC水平高于對(duì)照組,HDLC低于對(duì)照組,提示血脂異常與MI有關(guān)。
Lp-PLA2基因位于6p21.2-p12[9],Y160X突變導(dǎo)致氨基酸由酪氨酸(Tyr,Y)變?yōu)榻K止密碼子,突變后肽鏈不完整,空間構(gòu)象及功能都可能改變。本結(jié)果顯示,病例組AT、AG基因型以及A等位基因的分布頻率均明顯高于對(duì)照組,提示Y160X位點(diǎn)突變可能與MI的發(fā)病相關(guān)。
Logistic回歸分析結(jié)果顯示,AA基因型與MI關(guān)系密切,是MI的獨(dú)立危險(xiǎn)因素,提示Lp-PLA2基因突變與MI有關(guān)。結(jié)果還顯示血清Lp-PLA2的水平也與MI有關(guān),我們推測(cè)Lp-PLA2可能通過刺激IL-6、抑制IL-10而促進(jìn)了MI的發(fā)生,但具體機(jī)制還有待深入研究。
[1] WANG Q,HAO Y,MO X,et al.Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population[J].Mamm Genome,2015,26(3-4):191-199.
[2] MAIOLINO G,LENZINI L,PEDON L,et al.Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease[J].Cardiovasc Med (Hagerstown),2015,16(3):259.
[3] 張明明,盧亞敏,劉欣,等.石家莊地區(qū)肥胖人群KCTD15基因多態(tài)性與白細(xì)胞介素-35的關(guān)系[J].廣東醫(yī)學(xué),2015,36(23):3682-3685.
[4] ZHAO W,MA S T,CUI L Q.Meta-analysis of angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction in Han Chinese[J].Genet Mol Res,2015,14(3):8068-8076.
[5] LEI J,ZHU F,ZHANG Y,et al.Transient receptor potential vanilloid subtype 1 inhibits inflammation and apoptosis via the release of calcitonin gene-related peptide in the heart after myocardial infarction[J].Cardiology,2016,134(4):436-443.
[6] 虞春雷,李艷志,任利群.心率變異性及高敏C反應(yīng)蛋白與冠狀動(dòng)脈病變程度及預(yù)后的相關(guān)性研究[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2014,33(1):58-62.
[7] RIDKER P M.From C-reactive protein to interleukin-6 to interleukin-1:moving upstream to identify novel targets for atheroprotection[J].Circ Res,2016,118(1):145-156.
[8] MOBINI M,MORTAZAVI M,NADI S,et al.Significant roles played by interleukin-10 in outcome of pregnancy[J].Iran J Basic Med Sci,2016,19(2):119-124.
[9] VITTOS O,TOANA B,VITTOS A,et al.Lipoprotein-associated phospholipase A2 (Lp-PLA2):a review of its role and significance as a cardiovascular biomarker[J].Biomarkers,2012,17(4):289-302.
Significance of detection the Y160X site polymorphism of Lp-PLA2 gene in patients with myocardial infarction
ZHANG Ming-ming1,YU Yue-qing1,Zhao Pei1,YANG Chao-ju1,GAO Wei1,LI Ya-li2,LI Fang3
(1.DepartmentofMedicalLaboratory;2.DepartmentofReproductionandGenetics;3.DepartmentofRheumaticImmunology;HebeiGeneralHospital,Shijiazhuang050051,China)
Objective: To investigate the relationship between Y160X site polymorphism of Lp-PLA2 gene and myocardial infarction(MI).Methods:Y160X site polymorphism of Lp-PLA2 gene was tested in case group and control group.Logistic regression analysis was used to analyze relationship between Y160X site polymorphism of Lp-PLA2 gene and MI.Serum Lp-PLA2,lipids,glucose,HsCRP,IL-6,IL-10 of the 2 groups were detected simultaneously.Results:The serum levels of TC,TG,LDL-C,Lp-PLA2,HsCRP,IL-6,and positivie rate of family history in case group were higher than those in control group;while the levels of HDL-C,IL-10 were lower than those in control group (P<0.05).Levels of Lp-PLA2,HsCRP,IL-6 decreased after 1 week,1month,whereas the level of IL-10 increased (P<0.05).Genotype of Lp-PLA2 gene was risk factor of MI.Conclusions:The Y160X(T/A) site polymorphism of LP-PLA2 gene may be one pathogeny of MI.
Lp-PLA2 gene;gene polymorphism;myocardial infarction;genetic susceptibility
2016-08-07
2016-08-29
河北省科技支撐項(xiàng)目資助項(xiàng)目(16277771D)
張明明(1976-),女,河北昌黎人,副主任技師。E-mail:zhangmm197612@126.com
張明明,于悅卿,趙培,等.心肌梗死患者Lp-PLA2基因Y160X位點(diǎn)多態(tài)性檢測(cè)的意義[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2017,36(1):40-43.
R446.1;R541.4
A
1671-6264(2017)01-0040-04
10.3969/j.issn.1671-6264.2017.01.010